Online inquiry

IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12174MR)

This product GTTS-WQ12174MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12174MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11283MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ9032MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ972MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ15843MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ1380MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ3420MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ4785MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ6148MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-675
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW